Paul Choi
Stock Analyst at Goldman Sachs
(3.59)
# 1,529
Out of 4,479 analysts
66
Total ratings
52.63%
Success rate
4.6%
Average return
Main Sectors:
25 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOSS Gossamer Bio | Maintains: Buy | $8 | $0.96 | +733.51% | 4 | Jun 17, 2024 | |
| RGNX REGENXBIO | Initiates: Buy | $38 | $10.75 | +253.49% | 1 | Jun 7, 2024 | |
| PTCT PTC Therapeutics | Maintains: Sell | $18 → $32 | $30.39 | +5.30% | 5 | May 28, 2024 | |
| ARVN Arvinas | Initiates: Buy | $70 | $24.85 | +181.69% | 1 | Feb 1, 2024 | |
| DVAX Dynavax Technologies | Initiates: Neutral | $20 | $11.08 | +80.51% | 1 | Feb 1, 2024 | |
| HCM HUTCHMED (China) | Maintains: Neutral | $15 → $17 | $17.22 | -1.28% | 5 | Nov 10, 2023 | |
| CYTK Cytokinetics | Initiates: Buy | $50 | $54.84 | -8.83% | 1 | Nov 9, 2023 | |
| PHAT Phathom Pharmaceuticals | Maintains: Neutral | $9 → $10 | $10.25 | -2.44% | 5 | Nov 3, 2023 | |
| URGN UroGen Pharma | Maintains: Neutral | $11 → $18 | $15.14 | +18.89% | 2 | Jul 31, 2023 | |
| KNSA Kiniksa Pharmaceuticals | Maintains: Buy | $22 → $32 | $18.45 | +73.44% | 1 | Jul 26, 2023 | |
| VIR Vir Biotechnology | Maintains: Buy | $51 → $28 | $8.85 | +216.38% | 6 | Jul 21, 2023 | |
| AMRN Amarin Corporation | Maintains: Sell | $1.5 → $1 | $0.71 | +41.84% | 5 | Jul 20, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $29 → $50 | $24.91 | +100.72% | 4 | Jul 18, 2023 | |
| FHTX Foghorn Therapeutics | Maintains: Buy | $21 → $19 | $5.44 | +249.26% | 3 | Jun 29, 2023 | |
| FGEN FibroGen | Maintains: Sell | $16 → $2 | $0.74 | +169.18% | 7 | Jun 27, 2023 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $60 | $36.56 | +64.11% | 1 | Dec 14, 2022 | |
| ASND Ascendis Pharma | Initiates: Buy | $174 | $136.27 | +27.69% | 1 | Oct 20, 2022 | |
| PMVP PMV Pharmaceuticals | Maintains: Buy | $43 → $25 | $1.57 | +1,492.36% | 3 | May 24, 2022 | |
| ESPR Esperion Therapeutics | Maintains: Sell | $3.5 → $3 | $2.34 | +28.21% | 2 | May 24, 2022 | |
| ALLK Allakos | Maintains: Neutral | $10 → $4 | $0.84 | +375.85% | 3 | May 24, 2022 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Buy | n/a | $34.17 | - | 1 | Oct 6, 2021 | |
| RDUS Radius Health | Assumes: Buy | n/a | $14.67 | - | 1 | Mar 22, 2021 | |
| SWTX SpringWorks Therapeutics | Assumes: Buy | n/a | $37.27 | - | 1 | Mar 22, 2021 | |
| NBIX Neurocrine Biosciences | Downgrades: Neutral | n/a | $137.49 | - | 1 | Jun 29, 2020 | |
| NKTR Nektar Therapeutics | Upgrades: Neutral | n/a | $1.17 | - | 1 | Mar 30, 2020 |
Gossamer Bio
Jun 17, 2024
Maintains: Buy
Price Target: $8
Current: $0.96
Upside: +733.51%
REGENXBIO
Jun 7, 2024
Initiates: Buy
Price Target: $38
Current: $10.75
Upside: +253.49%
PTC Therapeutics
May 28, 2024
Maintains: Sell
Price Target: $18 → $32
Current: $30.39
Upside: +5.30%
Arvinas
Feb 1, 2024
Initiates: Buy
Price Target: $70
Current: $24.85
Upside: +181.69%
Dynavax Technologies
Feb 1, 2024
Initiates: Neutral
Price Target: $20
Current: $11.08
Upside: +80.51%
HUTCHMED (China)
Nov 10, 2023
Maintains: Neutral
Price Target: $15 → $17
Current: $17.22
Upside: -1.28%
Cytokinetics
Nov 9, 2023
Initiates: Buy
Price Target: $50
Current: $54.84
Upside: -8.83%
Phathom Pharmaceuticals
Nov 3, 2023
Maintains: Neutral
Price Target: $9 → $10
Current: $10.25
Upside: -2.44%
UroGen Pharma
Jul 31, 2023
Maintains: Neutral
Price Target: $11 → $18
Current: $15.14
Upside: +18.89%
Kiniksa Pharmaceuticals
Jul 26, 2023
Maintains: Buy
Price Target: $22 → $32
Current: $18.45
Upside: +73.44%
Vir Biotechnology
Jul 21, 2023
Maintains: Buy
Price Target: $51 → $28
Current: $8.85
Upside: +216.38%
Amarin Corporation
Jul 20, 2023
Maintains: Sell
Price Target: $1.5 → $1
Current: $0.71
Upside: +41.84%
BridgeBio Pharma
Jul 18, 2023
Maintains: Buy
Price Target: $29 → $50
Current: $24.91
Upside: +100.72%
Foghorn Therapeutics
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $5.44
Upside: +249.26%
FibroGen
Jun 27, 2023
Maintains: Sell
Price Target: $16 → $2
Current: $0.74
Upside: +169.18%
Xenon Pharmaceuticals
Dec 14, 2022
Initiates: Buy
Price Target: $60
Current: $36.56
Upside: +64.11%
Ascendis Pharma
Oct 20, 2022
Initiates: Buy
Price Target: $174
Current: $136.27
Upside: +27.69%
PMV Pharmaceuticals
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.57
Upside: +1,492.36%
Esperion Therapeutics
May 24, 2022
Maintains: Sell
Price Target: $3.5 → $3
Current: $2.34
Upside: +28.21%
Allakos
May 24, 2022
Maintains: Neutral
Price Target: $10 → $4
Current: $0.84
Upside: +375.85%
Biohaven Pharmaceutical Holding Company
Oct 6, 2021
Maintains: Buy
Price Target: n/a
Current: $34.17
Upside: -
Radius Health
Mar 22, 2021
Assumes: Buy
Price Target: n/a
Current: $14.67
Upside: -
SpringWorks Therapeutics
Mar 22, 2021
Assumes: Buy
Price Target: n/a
Current: $37.27
Upside: -
Neurocrine Biosciences
Jun 29, 2020
Downgrades: Neutral
Price Target: n/a
Current: $137.49
Upside: -
Nektar Therapeutics
Mar 30, 2020
Upgrades: Neutral
Price Target: n/a
Current: $1.17
Upside: -